Long Term Outcome of High-Dose Salvage Therapy for Patients with Early Stage Hodgkin Lymphoma (HL) Who Failed Initial Treatment with Combined Modality Treatment or Chemotherapy Alone
Andreas Rimner
Relapse of Hodgkin Lymphoma after Autologous Stem Cell Transplantation (ASCT): Identi cation of Prognostic Factors Predicting Outcome
Carmen Martinez
Allogeneic Stem Cell Transplantation for Hodgkin Lymphoma: a Retrospective Analysis of Data from the German Stem cell Transplantation Registry (DRST)
Christoph Scheid
10:30 – 12:00
Room: Großer Saal
Scientific SessionNew drugs
Peter Johnson
Anas Younes
SGN-35
Robert Chen
LBH-589
Anas Younes
Everolimus for Relapsed/Refractory HL
Patrick Johnston
Lenalidomide
Nancy Bartlett
Extended Follow-Up of the Safety of
131I Radiolabelled Anti-CD25 Antibody, Basiliximab, in Patients with CD25-Positive, Refractory Hodgkin Lymphoma
Neha Bhatnagar
Initial Results from the SAPHIRE Study: a Phase II Trial with the Novel Oral Histone Deacetylase (HDAC) Inhibitor Resminostat in Relapsed or Refractory Hodgkin Lymphoma Patients
Jan Walewski
12:00 – 13:15
Room: Großer Saal
Satellite SymposiumNew Mobilisation Strategies in Autologous Stem Cell Transplantation
Norbert Schmitz
The Role and Challenges of Autologous Transplantation in Hodgkin Lymphoma
Karl Peggs
Optimizing Stem Cell Mobilization with Plerixafor in Hodgkin Lymphoma
Peter Dreger
13:15 – 14:00
Room: Kleiner Saal
Main ProgramPosterwalk
14:00 – 15:30
Room: Großer Saal
Scientific SessionPET
Markus Dietlein
Aaron Polliack
PET for Lymphoma Staging
Bruce Cheson
Interim PET
Andrea Gallamini
PET during Follow-Up
Martin Hutchings
Contribution of PET/CT in the Design of the Involved Node Radiotherapy (INRT) Concept for Patients with Localized Hodgkin Lymphoma: Preliminary Results on 117 Patients entered in the H10 Trial
Theodore Girinsky
Early Interim FDG-PET during Intensi ed BEACOPP Therapy for Advanced-Stage Hodgkin Lymphoma Shows a Lower Positive Predictive Value than during ABVD
Francesca Fiore
A Bone Marrow Biopsy is Not Necessary in the Staging of Hodgkin Lymphoma (HL) Patients in the FDG-PET Era
Simon Richardson
16:00 – 17:30
Room: Großer Saal
Scientific SessionAdvanced Stage
George Canellos
Patrice Carde
Update on Stanford V
Ranjana Advani
Debate: Kairos or Chronos? Early versus Late Intensi cation in Advanced HL
Patrice Carde
Volker Diehl
Richard Fisher
HD15-PET: Final Analysis
Andreas Engert
Intensi ed ABVD for Newly Diagnosed Patients with Advanced-Stage Classical Hodgkin Lymphoma
Filippo Russo
BEACOPP is Superior to ABVD in Patients with Advanced Hodgkin Lymphoma and High Tumor Burden